Get started
GILEAD SCIENCESGILEAD SCIENCESGILEAD SCIENCES

GILEAD SCIENCES

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

GIS trade ideas

GILD is a dangerous buy, but a buy nonetheless for me.There is a lot NOT to like about this trade. Yes, I see how far it has run. Yes, I see how fast it is falling. Yes, I see the gap from 96 to 102 that “must” be filled. Yes, the market overall has been unhelpful of late. I realize all of it and I wouldn’t necessarily recommend anyone follow me on this trade because of all of that. Here’s my “bull” case, such that it is with the way I trade. It's solidly in a long term uptrend. I know I’m jinxing myself with this, but GILD hasn’t had a trade with my system last longer than 5 days in almost a year. I did one last Friday that took 1 day to pay off, so going back so soon is REALLY tempting fate. But I am a slave to the data. The long term W/L record at this point is 988-0 for GILD. The average gain for those trades is +2.55% in an average of 13 trading days. The vast majority have closed in 2 days or less. Those numbers are a compelling argument for me. It is very possible, given the recent market action and its own price action, that this will be a longer than average trade in GILD. But it could also be like last Friday’s trade, too - one and done. There isn’t much else that is appealing to my algo right now - yesterday there was literally only one large cap stock that was a buy and it wasn’t in the top half of my rankings, so I didn’t trade it. Today this is one of fewer than 10, and the others are all lower tier stocks for me, historically. So here’s hoping I catch lightning in a bottle twice in one week with this stock. Entered my initial position at the close for 107.51. Per my usual strategy, I'll add to my position at the close on any day it still rates as a “buy” and I will use FPC (first profitable close) to exit any lot on the day it closes at any profit. As always - this is intended as "edutainment" and my perspective on what I am or would be doing, not a recommendation for you to buy or sell. Act accordingly and invest at your own risk. DYOR and only make investments that make good financial sense for you in your current situation.
NASDAQ:GILDLong
by redwingcoach
1
Gilead Sciences (GILD) Soars 4.93% on Strong Q4 Earnings ReportsGilead Sciences (NASDAQ: NASDAQ:GILD ) is making waves in the biotech sector after delivering a stellar fourth-quarter earnings report that not only crushed Wall Street expectations but also set the stage for a promising 2025. The stock surged 4.50% in premarket trading on Wednesday, signaling strong investor confidence in the company’s growth trajectory. Quarter and Optimistic Guidance Gilead’s Q4 earnings report was nothing short of impressive. The company posted adjusted earnings of $1.90 per share, a 10.5% year-over-year increase, and handily beat analysts’ estimates of $1.74. Revenue climbed 6% to $7.57 billion, surpassing the consensus forecast of $7.15 billion. HIV Franchise Shines Bright Gilead’s HIV portfolio remains its crown jewel. Biktarvy, the company’s flagship HIV treatment, generated $3.8 billion in sales, up 21% year-over-year and well ahead of the $3.47 billion forecast. Descovy, another HIV drug, also outperformed expectations, with sales rising 21% to $616 million. Combined, Gilead’s HIV product sales reached $5.45 billion, up 16% from the previous year. Looking ahead, Gilead is poised to expand its HIV franchise further with the anticipated mid-2025 launch of lenacapavir, a twice-yearly injectable for HIV prevention. The U.S. Food and Drug Administration (FDA) is expected to make a decision on the drug by mid-2024, and its approval could be a significant growth catalyst. Oncology and Liver Disease: Steady Growth Gilead’s oncology and liver disease segments also contributed to the strong quarter. Sales of its cell therapies for cancer treatment rose 5% to $488 million, beating expectations of $476 million. Trodelvy, a cancer drug, saw sales jump 19% to $355 million, surpassing the $324 million forecast. Liver disease treatments brought in $719 million, up 4% year-over-year. Veklury: The Only Blemish The only downside in Gilead’s report was Veklury, its COVID-19 treatment. Sales plummeted 53% to $337 million due to lower hospitalizations, particularly in the U.S. Upbeat 2025 Guidance Gilead’s bullish outlook for 2025 further fueled investor optimism. The company expects adjusted earnings of $7.70 to $8.10 per share on product sales of $28.2 billion to $28.6 billion. The midpoint of this guidance exceeds analysts’ estimates of $7.61 per share and $28.35 billion in revenue. Technical Analysis From a technical perspective, Gilead’s stock is showing strong bullish signals. As of Wednesday’s premarket trading, GILD is up 4.93%, poised to form a gap-up pattern upon market open. Key Levels to Watch - Resistance: A breakout above the 1-month high of $100 could serve as a critical catalyst for a sustained bullish run. This level represents a psychological barrier, and a decisive move above it could attract more buyers. - Support: In the event of a pullback, immediate support lies at the 65% Fibonacci retracement level, which aligns with the $92 mark. This level could act as a springboard for renewed upward momentum. RSI Indicates Room for Growth The Relative Strength Index (RSI) stands at 55, indicating that the stock is neither overbought nor oversold. This suggests there is ample room for further upside, especially if the broader market sentiment remains favorable. Conclusion Gilead Sciences (GILD) is firing on all cylinders, with a strong Q4 earnings beat, robust guidance for 2025, and a promising pipeline. The company’s leadership in the HIV market, coupled with its growing presence in oncology and liver disease, positions it well for long-term growth. From a technical standpoint, the stock is primed for a breakout, with key resistance and support levels offering clear markers for traders and investors.
NASDAQ:GILDLong
by DEXWireNews
Gilead Sciences (GILD): Will Support Hold or Will We See a Drop?We've neglected Gilead Sciences for a while, but it's time for an update. Unfortunately, our entry looking back wasn't ideal, as the stock has fallen below the 61.8% retracement level. It found support just below the 78.6% level, which marks the bottom of our range. This level was precisely touched, and we saw a relatively good movement upward from there. However, the outlook remains uncertain. We hope that the stock does not fall below this range bottom, as it would prompt us to consider cutting it. Our first take-profit target is at the range high around $86.5, but reaching this level will take time as Gilead Sciences is currently underperforming. Unlike most other stocks, Gilead Sciences operates in the research sector, not the tech sector. This means it follows a different cycle and is influenced by different capital flows. It tends to perform well when tech stocks do poorly. If tech stocks remain bullish, Gilead Science might continue to struggle. However, if there's a shift, Gilead Science could reverse and potentially reach up to $123, though this is quite far off. We are holding our position for now, hoping not to cut if the stock falls out of the range. If it does, we will take necessary action.
NASDAQ:GILDLong
by freeguy_by_wmc
Gilead Sciences (GILD): Pattern Still Intact—What’s the Plan?Let’s quickly review our open position in $GILD. We’ve managed to turn the whole chart around, and I hope everyone who bought in had the strength to sit it out. It was a close call with the stop loss, but now we’re up significantly, and we’ve moved our stop loss closer to $65.46. So far, we’re up 17%, and we don’t want to dictate when to take profits. If you’re in, do your own research and take profits whenever you feel comfortable—it's all up to you 👍. If you take a closer look, you’ll see that NASDAQ:GILD has been following a nice upward pattern: a surge, then three candles down, then another surge. I’m not sure how long this pattern will hold, but as long as we don’t retrace too much, we should be fine. I also like that we’re respecting all the key levels. The RSI is about to be overbought, so we might see another three candles down, but this time it could be a deeper pullback. We’ll see how it plays out, but we’re very pleased with this swing trade so far. Congratulations to everyone who’s been riding this wave 🍾.
NASDAQ:GILDLong
by freeguy_by_wmc
2
Gilead Sciences (GILD): First Take Profit in a High RangeGilead Sciences is now back trading at the high end of its range, and we’ve decided to take our first profit here. It’s crucial to respect range-bound trading, and there is a strong possibility of a pullback at this point. However, we don’t expect this pullback to reach the lower end of the range again but rather settle in the middle. If NASDAQ:GILD reclaims this range high, it could provide even more upside and new opportunities. We are also raising our stop loss to $65.80 to lock in gains. Gilead serves as our "natural hedge" against broader risk-on market conditions, and with a 40% bounce from the range low at the same time the S&P 500 is hitting new all-time highs, it’s clear that Gilead can benefit as well. We’re keeping a close eye on this stock, and if another opportunity arises, we’ll be ready to act.
NASDAQ:GILDLong
by freeguy_by_wmc
GILD will be selected for the new Tamiflu vaccine for Pandemic2It's no secret the elite are manufacturing pandemics to herd, destroy and remake society into a neofeudal system controlled by social credit scores. The next pandemic will be H1N1 which has already been shared within the news that milk in the markets has trace amounts of (no worry they say!). After the establishment rolls out bird-flu for everyone's summer bingo card - Gilead Sciences, the only company that manufactures Tamiflu with options, will be selected to mass create these new vaccines. The call options on this company are going crazy right now, July, August have a ton of OTM calls being bought, almost like someone is expecting this company to get the greenlight on something major. You could effectively buy .05 OTM calls on this company, but I'd wait a little longer. The TTM squeeze shows the last leg down is being finished. If the market's capitulate a little more, this would be a perfect time to buy those calls for this company.
NASDAQ:GILDLong
by EmptyEternity
1
GILD falling wedgeHi traders, Focusing on Gilead Sciences, Inc. (ticker symbol: GILD), we can see that it has formed a falling wedge pattern over the past few weeks, indicating a potential bullish reversal. Despite recent challenges, there are compelling reasons to consider a long position in this stock. Gilead Sciences has been a key player in the pharmaceutical industry, known for its innovative treatments in areas such as HIV/AIDS, hepatitis, and more recently, COVID-19. Despite recent market pressures, GILD fundamental strength remains intact, supported by its diverse portfolio of blockbuster drugs and ongoing research and development efforts. The falling wedge pattern, coupled with the oversold Relative Strength Index (RSI) suggests that the stock is undervalued and may be ripe for a reversal. As the stock approaches the apex of the falling wedge, and the key support level, we expect the trend reversal. The breakout above the upper trendline could signal a bullish move. Furthermore, recent news indicates that Gilead Sciences is exploring strategic initiatives to enhance its pipeline and drive future growth. This includes potential partnerships, acquisitions, and advancements in its drug development programs, which could serve as catalysts for a turnaround in the stock's performance. As the breakout of the falling wedge pattern becomes imminent, considering a long position upon confirmation of a break above the upper trendline may present an attractive opportunity for traders seeking to capitalize on the potential bullish reversal. Buy once the breakout occurs. 3 take profit levels / targets are shown on the chart
NASDAQ:GILDLong
by vf_investment
Gilead Sciences (GILD): Chances in Pharma Beyond TechGilead Sciences (GILD): NASDAQ:GILD We're aiming to diversify our portfolio beyond just tech stocks and the tech sector. We're now focusing on companies in the pharmaceutical industry, such as Gilead Sciences. Analyzing the weekly chart, we observed the largest surge since 2010 for Wave (3). We believe we've also completed Wave (4) at $56.56. The peak was at $123.27, marking our all-time high. This figure is our target for the minimum achievement for Wave 3. It's crucial, and significantly, we anticipate a high selling pressure at this level. Zooming in, we presume we are in Wave 2, expected to conclude between 61.8% and 78.6% retracement. This positions us with a relatively favorable risk-to-reward ratio on the daily chart. Should we drop below this 78.6% retracement level, we could fall back to $56. If that happens, we'll face a problem, potentially falling further for Wave (4) to a maximum of $30. If this decline doesn't materialize, we'll continue to anticipate an upward movement.
NASDAQ:GILDLong
by freeguy_by_wmc
1